BeiGene - About the company
BeiGene is a public company based in Cambridge (United States), founded in 2010 by . It operates as a Developer of targeted and immune-oncology drugs against cancer. BeiGene has raised $172M in funding from Hillhouse. The company has 578 active competitors, including 188 funded and 133 that have exited. Its top competitors include companies like Moderna, Incyte and Vir Biotechnology.
Company Details
Developer of targeted and immune-oncology drugs against cancer. The company's product pipeline includes oral small molecule inhibitors and monoclonal antibodies, such as BGB-3111, an oral inhibitor of Bruton tyrosine kinase, BGB-283, a B-RAF inhibitor; and BGB-290, a poly (ADP-ribose) polymerase inhibitor. Also, has another candidate BGB-108, a potentially differentiated PD-1 monoclonal antibody candidate.
- Website
- Email ID
- @beigene.com
- Phone Number
- +1
Key Metrics
Founded Year
2010
Location
Cambridge, United States
Stage
Public
Total Funding
in 6 rounds
Latest Funding Round
Investors
Ranked
2nd among 578 active competitors
Annual Revenue
as on Dec 31, 2020
Employee Count
as on Dec 31, 2022
Investment & Acquisitions
Similar Companies
Incyte &
Exit Details
Public
Legal entities associated with BeiGene
BeiGene is associated with 4 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Aug 27, 2015 | $309M (as on Dec 31, 2020) | 225 | 303 | |
Jan 15, 2019 | - | 936 | 810 | |
Dec 31, 2009 | - | 666 | 236 | |
Dec 26, 999 | - | 373 | 594 |
Get your free copy of BeiGene's company profile
BeiGene's funding and investors
BeiGene has raised a total funding of $172M over 6 rounds. Its first funding round was on May 02, 2011. Its latest funding round was a Post IPO round on Jul 15, 2020 for $2.1B. 1 investor participated in its latest round, which include T. Rowe Price, Temasek, Rock Springs Capital and Fidelity Investments.
BeiGene has 15 institutional investors including Hillhouse, T. Rowe Price and .
Here is the list of recent funding rounds of BeiGene:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Jul 15, 2020 | $2.1B | Post IPO | 7866186 | 3394529 | |
Oct 31, 2019 | $2.8B | Post IPO | 7103190 | 3591231 | |
May 13, 2015 | $97M | Series B | 2525383 | 9060360 |
Access funding benchmarks and valuations. Sign up today!View details of BeiGene's funding rounds and investors
BeiGene's founders and board of directors
The founders of BeiGene is . is the CEO of BeiGene.
View details of BeiGene's Founder profiles and Board Members
BeiGene's employee count trend
BeiGene has 1,090 employees as of Dec 22. The total employee count is 36.8% more than what it was in Dec 21. Here is BeiGene's employee count trend over the years:
Uncover BeiGene's growth story! Sign up today!BeiGene's Competitors and alternates
Top competitors of BeiGene include Moderna, Incyte and Vir Biotechnology. Here is the list of Top 10 competitors of BeiGene, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | Flagship Pioneering, WellingtonÌý&²¹³¾±è;Ìý | 86/100 |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | T. Rowe Price, TemasekÌý&²¹³¾±è;Ìý | 78/100 |
3rd | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | Tekla Capital Management, Ridgeback Capital ManagementÌý&²¹³¾±è;Ìý | 78/100 |
4th | Vir Biotechnology 2017, San Francisco (United States), Public | Developer of therapeutics for the treatment of infectious diseases | $216M | Alta Partners, Arch Venture PartnersÌý&²¹³¾±è;Ìý | 74/100 |
5th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | Tekla Capital Management, Ridgeback Capital ManagementÌý&²¹³¾±è;Ìý | 74/100 |
6th | Developer of antibodies for treating cancer | - | , Ridgeback Capital ManagementÌý&²¹³¾±è;Ìý | 73/100 | |
7th | Cidara Therapeutics 2013, San Diego (United States), Public | Developer of novel anti-infectives for infectious diseases (bacterial and fungal) | $78.4M | InterWest Partners, Aisling CapitalÌý&²¹³¾±è;Ìý | 72/100 |
8th | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | Venrock, New Enterprise AssociatesÌý&²¹³¾±è;Ìý | 72/100 |
9th | _1549346058109.png?height=40&width=40){kind=logo} ALX Oncology 2015, Burlingame (United States), Series C | Developer of immuno-oncology therapies for cancer treatment | $123M | Vivo Capital, Foresite CapitalÌý&²¹³¾±è;Ìý | 72/100 |
10th |  Ventyx Biosciences 2018, Encinitas (United States), Public | Developer of therapeutics to treat autoimmune diseases | $165M | Vivo Capital, OrbimedÌý&²¹³¾±è;Ìý | 71/100 |
_1586343560242.png?height=40&width=40){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on BeiGene's competitors? Click to see the top ones
BeiGene's Investments and acquisitions
BeiGene has not made any acquisitions yet. BeiGene has made 6 investments. Here is the list of latest three investments:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Jun 28, 2024 | Investments | 2021 | Huangpu, | |
Aug 11, 2023 | Investments | 2020 | Pittsburgh, United States | |
Nov 02, 2021 | Investments | 2020 | San Diego, United States |
Want to know more about where corporates are investing? Sign up today!See all investments by BeiGene
Reports related to BeiGene
Here is the latest report on BeiGene's sector:
View
News related to BeiGene
Media has covered BeiGene for a total of 90 events in the last 1 year, 39 of them have been about company updates and 8 about partnerships.
•
•
•
•
•
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about BeiGene
When was BeiGene founded?
BeiGene was founded in 2010.Where is BeiGene located?
BeiGene is located in Cambridge, United States.When was the latest funding round of BeiGene?
BeiGene's latest funding round was on Jul 15, 2020.What is the annual revenue of BeiGene?
Annual revenue of BeiGene is $309M as on Dec 31, 2020.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- Skildpot - Bengaluru based, 2023 founded, Unfunded company
- Poznan University of Life Sciences - Poznan based, 1919 founded, Funding Raised company
- Via Creative Tech - Mumbai based, 2020 founded, Unfunded company
- Social Spike Marketing Group - Halifax based, 2015 founded, Public company
- Do My Assignment UK - Poole based, 2024 founded, Unfunded company
- Social Dept - Los Angeles based, 2024 founded, Unfunded company
